orforglipron
Other research peptides · 2 suppliers · $0.37 to $0.52 per mg · 53 registered studies · 137 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
No PubChem compound record is pinned for this name, so no computed formula and no computed mass is printed here.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term orforglipron, read on 2026-09-20, returned 53 registered studies: 21 phase 1, 3 phase 2, 27 phase 3 and 2 phase 4.
Eli Lilly and Company is lead sponsor on 49 of the 53 records. The remaining 4 name 3 other organizations.
On the date read, the statuses those records carried were 32 completed, 9 recruiting and 7 active not recruiting, among others.
The earliest record the search returns is NCT03929744, first submitted 2019-04-25. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 137 records for the term orforglipron on 2026-09-20. Of those, 20 carry a clinical-trial publication type, and 9 of those carry Clinical Trial, Phase III. 68 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
The Drugs@FDA database holds application NDA 220934 under this name, sponsor ELI LILLY AND CO. Its listed products are marked Prescription in the same database.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
labelTwo groups must not be given Foundayo, the approved product. Anyone who has had medullary thyroid cancer or whose family has, including anyone with the inherited condition Multiple Endocrine Neoplasia type 2. And anyone who has had a serious allergic reaction to orforglipron or to anything else in the tablet.FOUNDAYO label · read 2026-09-19
labelIt carries a boxed warning, the strongest kind, and the reason is not what it is for the injected drugs in this class. The label says orforglipron does not work on rat and mouse GLP-1 receptors and produced no tumours in rodents. The warning is there because other drugs acting on the human GLP-1 receptor did cause thyroid tumours in rodents, and whether that matters for people has never been settled. So this is a warning inherited from the class rather than earned by this compound.FOUNDAYO label · read 2026-09-19
Foundayo is a prescription tablet made by Eli Lilly, approved under NDA220934. Powder and capsules sold as orforglipron are not that product.read 2026-09-19
What has not been published
- No PubChem compound record is pinned for this name, so no computed formula and no computed mass appears above.
Where a line above says nothing has been compiled here, that is a gap in this publication's record. Where it says nothing is indexed or registered, that is a gap in the public record.
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $0.37per mg | $198.956mg × 90 vials | Swiss Chemsrecord → | not transcribed | not transcribed | capsules, 6mg per capsule x90; the page states total compound content 540 mg and lists SKU ORF-6MG-90Cread 2026-09-19 |
| $0.52per mg | $279.996mg × 90 vials | Regentiderecord → | not transcribed | not transcribed | capsules, 6mg per capsule x90; listed on the page as Orforglipron 6mg GLP1-O (90 Capsules)read 2026-09-19 |
Read between 2026-09-19 and 2026-09-19. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-20. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-20. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-20.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.